144 related articles for article (PubMed ID: 38031271)
1. Design, Molecular Modeling, MD Simulations, Essential Dynamics, ADMET, DFT, Synthesis, Anti-proliferative, and Apoptotic Evaluations of a New Anti-VEGFR-2 Nicotinamide Analogue.
Eissa IH; Elkaeed EB; Elkady H; Yousef RG; Alsfouk BA; Elzahabi HSA; Ibrahim IM; Metwaly AM; Husein DZ
Curr Pharm Des; 2023; 29(36):2902-2920. PubMed ID: 38031271
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, Docking, DFT, MD Simulation Studies of a New Nicotinamide-Based Derivative: In Vitro Anticancer and VEGFR-2 Inhibitory Effects.
Elkaeed EB; Yousef RG; Elkady H; Gobaara IMM; Alsfouk BA; Husein DZ; Ibrahim IM; Metwaly AM; Eissa IH
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889478
[TBL] [Abstract][Full Text] [Related]
3. (
Yousef RG; Elkady H; Elkaeed EB; Gobaara IMM; Al-Ghulikah HA; Husein DZ; Ibrahim IM; Metwaly AM; Eissa IH
Molecules; 2022 Nov; 27(22):. PubMed ID: 36431818
[TBL] [Abstract][Full Text] [Related]
4. Anti-breast cancer potential of a new xanthine derivative: In silico, antiproliferative, selectivity, VEGFR-2 inhibition, apoptosis induction and migration inhibition studies.
Eissa IH; Yousef RG; Elkady H; Elkaeed EB; Alsfouk BA; Husein DZ; Asmaey MA; Ibrahim IM; Metwaly AM
Pathol Res Pract; 2023 Nov; 251():154894. PubMed ID: 37857034
[TBL] [Abstract][Full Text] [Related]
5. Exploring the anticancer properties of a new nicotinamide analogue: Investigations into in silico analysis, antiproliferative effects, selectivity, VEGFR-2 inhibition, apoptosis induction, and migration suppression.
Eissa IH; Yousef RG; Sami M; Elkaeed EB; Alsfouk BA; Ibrahim IM; Husein DZ; Elkady H; Metwaly AM
Pathol Res Pract; 2023 Dec; 252():154924. PubMed ID: 37956639
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2.
Yousef RG; Eldehna WM; Elwan A; Abdelaziz AS; Mehany ABM; Gobaara IMM; Alsfouk BA; Elkaeed EB; Metwaly AM; Eissa IH
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807326
[TBL] [Abstract][Full Text] [Related]
7. New thiazolidine-2,4-diones as potential anticancer agents and apoptotic inducers targeting VEGFR-2 kinase: Design, synthesis, in silico and in vitro studies.
Elkady H; Mahdy HA; Taghour MS; Dahab MA; Elwan A; Hagras M; Hussein MH; Ibrahim IM; Husein DZ; Elkaeed EB; Alsfouk AA; Metwaly AM; Eissa IH
Biochim Biophys Acta Gen Subj; 2024 Jun; 1868(6):130599. PubMed ID: 38521471
[TBL] [Abstract][Full Text] [Related]
8. Design, semi-synthesis, anti-cancer assessment, docking, MD simulation, and DFT studies of novel theobromine-based derivatives as VEGFR-2 inhibitors and apoptosis inducers.
Eissa IH; Yousef RG; Elkady H; Elkaeed EB; Alsfouk AA; Husein DZ; Ibrahim IM; Elhendawy MA; Godfrey M; Metwaly AM
Comput Biol Chem; 2023 Dec; 107():107953. PubMed ID: 37673011
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
10. Anti-cancer and immunomodulatory evaluation of new nicotinamide derivatives as potential VEGFR-2 inhibitors and apoptosis inducers:
Yousef RG; Elwan A; Gobaara IMM; Mehany ABM; Eldehna WM; El-Metwally SA; A Alsfouk B; Elkaeed EB; Metwaly AM; Eissa IH
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2206-2222. PubMed ID: 35980113
[TBL] [Abstract][Full Text] [Related]
11. New thiazolidine-2,4-diones as effective anti-proliferative and anti-VEGFR-2 agents: Design, synthesis, in vitro, docking, MD simulations, DFT, ADMET, and toxicity studies.
Elkady H; Abuelkhir AA; Rashed M; Taghour MS; Dahab MA; Mahdy HA; Elwan A; Al-Ghulikah HA; Elkaeed EB; Ibrahim IM; Husein DZ; Metwaly A; Eissa IH
Comput Biol Chem; 2023 Dec; 107():107958. PubMed ID: 37714080
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, anti-proliferative evaluation, docking, and MD simulations studies of new thiazolidine-2,4-diones targeting VEGFR-2 and apoptosis pathway.
Taghour MS; Elkady H; Eldehna WM; El-Deeb N; Kenawy AM; Elkaeed EB; Alsfouk BA; Alesawy MS; Husein DZ; Metwaly AM; Eissa IH
PLoS One; 2022; 17(9):e0272362. PubMed ID: 36149902
[TBL] [Abstract][Full Text] [Related]
13. Discovery of new nicotinamides as apoptotic VEGFR-2 inhibitors: virtual screening, synthesis, anti-proliferative, immunomodulatory, ADMET, toxicity, and molecular dynamic simulation studies.
Yousef RG; Ibrahim A; Khalifa MM; Eldehna WM; Gobaara IMM; Mehany ABM; Elkaeed EB; Alsfouk AA; Metwaly AM; Eissa IH
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1389-1403. PubMed ID: 35577416
[TBL] [Abstract][Full Text] [Related]
14. Discovery of new quinoline and isatine derivatives as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative, docking and MD simulation studies.
Taghour MS; Elkady H; Eldehna WM; El-Deeb N; Kenawy AM; Abd El-Wahab AE; Elkaeed EB; Alsfouk BA; Metwaly AM; Eissa IH
J Biomol Struct Dyn; 2023; 41(21):11535-11550. PubMed ID: 36617888
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis.
Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE
Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320
[TBL] [Abstract][Full Text] [Related]
16. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
[TBL] [Abstract][Full Text] [Related]
17. Discovery of new anticancer thiourea-azetidine hybrids: design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies.
Parmar DR; Soni JY; Guduru R; Rayani RH; Kusurkar RV; Vala AG; Talukdar SN; Eissa IH; Metwaly AM; Khalil A; Zunjar V; Battula S
Bioorg Chem; 2021 Oct; 115():105206. PubMed ID: 34339975
[TBL] [Abstract][Full Text] [Related]
18. New quinoline and isatin derivatives as apoptotic VEGFR-2 inhibitors: design, synthesis, anti-proliferative activity, docking, ADMET, toxicity, and MD simulation studies.
Elkaeed EB; Taghour MS; Mahdy HA; Eldehna WM; El-Deeb NM; Kenawy AM; A Alsfouk B; Dahab MA; Metwaly AM; Eissa IH; El-Zahabi MA
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2191-2205. PubMed ID: 35975321
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, molecular docking, in silico ADMET profile and anticancer evaluations of sulfonamide endowed with hydrazone-coupled derivatives as VEGFR-2 inhibitors.
Sayed AM; Taher FA; Abdel-Samad MRK; El-Gaby MSA; El-Adl K; Saleh NM
Bioorg Chem; 2021 Mar; 108():104669. PubMed ID: 33515863
[TBL] [Abstract][Full Text] [Related]
20. Discovery of New VEGFR-2 Inhibitors: Design, Synthesis, Anti-Proliferative Evaluation, Docking, and MD Simulation Studies.
Elkaeed EB; Yousef RG; Khalifa MM; Ibrahim A; Mehany ABM; Gobaara IMM; Alsfouk BA; Eldehna WM; Metwaly AM; Eissa IH; El-Zahabi MA
Molecules; 2022 Sep; 27(19):. PubMed ID: 36234734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
